Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bayesian adaptive phase II trial of anlotinib or penpulimab for recurrent glioblastoma after chemoradiotherapy
ChiCTR2300074437Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2023
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of anlotinib, penpulimab and temozolomide in glioblastoma (GBM) (4 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Encephaledema volume and Progression-free survival. Started Aug 2023; status: recruiting.
02
Drugs
anlotinibpenpulimabtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2300074437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074437.